期刊文献+

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

原文传递
导出
摘要 Dear Editor,Breast cancer(BC)is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide[1].Despite the advances in BC targeted therapies,cytotoxic chemotherapy is still widely used[2].However,around 20%-30%of BC patients develop metastasis after treatment as a consequence of drug resistance[3].In this context,microRNAs have emerged as potential therapeutic targets to overcome therapy resistance[4].Therefore,we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin,one of the most effective chemotherapeutic agents used in BC.Methods are detailed in Supplementary Materials.
出处 《Cancer Communications》 SCIE 2022年第12期1412-1416,共5页 癌症通讯(英文)
基金 supported by Spanish Government and cofinanced by FEDER Funds(PI18/01219,PI21/01351,PI18/00382,and RTI2018-100910-B-C41) CIBERBBN(CB07/01/2012) CIBERONC(CB16/12/00481) the Generalitat Valenciana(project PROMETEO 2018/024) funded by Generalitat Valenciana(ACIF/2016/030) funded by Asociación Española Contra el Cancer. funded by Instituto de Salud Carlos Ⅲ and the European Social Fund for the financial support“Sara Borrell”(CD19/00038) funded by Ministerio de Ciencia e Innovación(FPU grant) funded by Sociedad Española de Oncología Médica(Río Hortega-SEOM).
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部